AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21075038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates mat exercises
Number of subjects: 34
Study 21075038 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 34
Study 19711195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive search filter
Number of subjects: 0
Study 19711195 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise search filter
Number of subjects: 0
Study 16912489 — intervention group
Group type: EXPERIMENTAL
Intervention: Almodin‐Moron trocar
Number of subjects: 6
Study 16912489 — intervention group
Group type: COMPARATOR
Intervention: Tulipan‐Bruner trocar
Number of subjects: 6
Study 15292036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding (NG or PEG feeding)
Number of subjects: 38
Study 15292036 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding (control group)
Number of subjects: 38
Study 15353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 537
Study 15353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg/day
Number of subjects: 537
Study 15353388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 15353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg/day
Number of subjects: 537
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite material
Number of subjects: 197
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer Photac-Fil
Number of subjects: 197
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 197
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 197
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric
Number of subjects: 197
Study 10872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion/non-carious cervical cavities
Number of subjects: 197
Study 9174136 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinucleotide repeat polymorphism (GCT)n within the MICA gene
Number of subjects: 604
Study 9174136 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) combined with fluorescent‐based automated fragment detection technology
Number of subjects: 604
Study 8261811 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycolic acid lotion
Number of subjects: 35
Study 8261811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3949246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal instillation of bupivacaine 2 mg/kg bw
Number of subjects: 0
Study 3052266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (up to 30 mg per day)
Number of subjects: 7
Study 3052266 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study 31154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour language therapy (CBLT) programme delivered in 24 group sessions over 12 weeks
Number of subjects: 92
Study 31154887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 92
Study 28780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimaglermin alfa (0.8mg/kg and 2.6mg/kg) in mice
Number of subjects: 0
Study 28780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimaglermin alfa in diabetic mice
Number of subjects: 0
Study 28780372 — intervention group
Group type: COMPARATOR
Intervention: Cimaglermin alfa in human heart failure patients
Number of subjects: 0
Study 25472825 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) (n=61)
Number of subjects: 120
Study 25472825 — intervention group
Group type: COMPARATOR
Intervention: PI-based ART (n=59)
Number of subjects: 120
Study 23433852 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily DRV/r
Number of subjects: 429
Study 23433852 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily DRV/r
Number of subjects: 429
Study 20840345 — intervention group
Group type: EXPERIMENTAL
Intervention: Licochalcone A (LA) lotion, applied twice daily for 6 weeks
Number of subjects: 30
Study 20840345 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) lotion, applied twice daily for 6 weeks
Number of subjects: 30
Study 19447940 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based therapeutic exercise
Number of subjects: 3800
Study 19447940 — intervention group
Group type: COMPARATOR
Intervention: Land-based therapeutic exercise (fewer than 12 direct supervision occasions)
Number of subjects: 3800
Study 17301824 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/daily)
Number of subjects: 57
Study 17301824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/daily)
Number of subjects: 57
Study 17301824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (losartan 50 mg/daily + ramipril 5 mg/daily)
Number of subjects: 57
Study 15014270 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity
Number of subjects: 105
Study 15014270 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physical therapy)
Number of subjects: 105
Study 11160464 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy at home
Number of subjects: 0
Study 11160464 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy as an outpatient
Number of subjects: 0
Study 11160464 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study 9932142 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA + EPA
Number of subjects: 65
Study 9932142 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil placebo
Number of subjects: 65
Study 9932142 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA + EPA (after switching from placebo)
Number of subjects: 65
Study 9932142 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA + EPA (continued treatment)
Number of subjects: 65
Study 8050541 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (8 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 8050541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3056506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (2 g single doses on days 1 and 3) for male partners
Number of subjects: 107
Study 3056506 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for male partners
Number of subjects: 107
Study 31901403 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 300
Study 31901403 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive for depression
Number of subjects: 300
Study 31901403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (male)
Number of subjects: 300
Study 31901403 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced disease
Number of subjects: 300
Study 31901403 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for place of death
Number of subjects: 300
Study 30659070 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis)
Number of subjects: 411
Study 30659070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 30659070 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 411
Study 28669288 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMCare collaborative care depression intervention (choice of brief interpersonal psychotherapy or pharmacotherapy or both)
Number of subjects: 164
Study 28669288 — intervention group
Group type: COMPARATOR
Intervention: Enhanced maternity support services (MSS-Plus)
Number of subjects: 164
Study 25666215 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel Management support (with PMAs)
Number of subjects: 8153
Study 25666215 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel Management support plus education
Number of subjects: 8153
Study 25666215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no panel management support)
Number of subjects: 8153
Study 22878873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential HRP scoring protocol (automatic and then manual for residual cases)
Number of subjects: 366
Study 22878873 — intervention group
Group type: COMPARATOR
Intervention: Manual HRP scoring
Number of subjects: 366
Study 22878873 — intervention group
Group type: COMPARATOR
Intervention: Automatic HRP scoring
Number of subjects: 366
Study 22878873 — intervention group
Group type: COMPARATOR
Intervention: Subsequent manual HRP scoring
Number of subjects: 366
Study 21311168 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric ergometer sessions (EET)
Number of subjects: 28
Study 21311168 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional strength training (RET)
Number of subjects: 28
Study 19338158 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia injection (SI) plus composite amino acid (CAA) for 7 days
Number of subjects: 106
Study 19338158 — intervention group
Group type: COMPARATOR
Intervention: Composite amino acid (CAA) alone for 7 days
Number of subjects: 106
Study 16412750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 44
Study 16412750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study 15255164 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Number of subjects: 0
Study 15255164 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan in combination with gemcitabine, taxanes, and other new agents
Number of subjects: 0
Study 15255164 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan combined with a platinum agent
Number of subjects: 0
Study 12587182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (2.5%) infusion
Number of subjects: 17
Study 12587182 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) infusion
Number of subjects: 17
Study 9577356 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 250 micrograms twice daily
Number of subjects: 58
Study 9577356 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study 8169175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually abused children
Number of subjects: 49
Study 8169175 — intervention group
Group type: COMPARATOR
Intervention: Non-sexually abused children
Number of subjects: 49
Study 8169175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 3285637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (400 IU, 5-7 times weekly)
Number of subjects: 51
Study 3285637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months (Rx-Naïve)
Number of subjects: 89
Study 30355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic TPTD for 48 months (Rx-Naïve)
Number of subjects: 89
Study 30355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months (ALN-Rx)
Number of subjects: 89
Study 30355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic TPTD for 48 months (ALN-Rx)
Number of subjects: 89
Study 28980452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide (initial dose 80 mg/day, can be doubled if poor response)
Number of subjects: 0
Study 28980452 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of furosemide (twice-daily bolus injection)
Number of subjects: 0
Study 28980452 — intervention group
Group type: EXPERIMENTAL
Intervention: High diuretic dose (furosemide >120 mg/day)
Number of subjects: 0
Study 28980452 — intervention group
Group type: COMPARATOR
Intervention: Low diuretic dose (furosemide ≤120 mg/day)
Number of subjects: 0
Study 24978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative blogs
Number of subjects: 181
Study 24978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant blog comments
Number of subjects: 181
Study 24978046 — intervention group
Group type: EXPERIMENTAL
Intervention: Defiant blog comments
Number of subjects: 181
Study 24978046 — intervention group
Group type: COMPARATOR
Intervention: Non-narrative blogs
Number of subjects: 181
Study 23883138 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit plus implementation support
Number of subjects: 2520
Study 23883138 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 2520
Study 21062921 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered 100 kVp images
Number of subjects: 1152
Study 21062921 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp with a filter
Number of subjects: 1152
Study 21062921 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp and 100 kVp images with nonlinear noise filter
Number of subjects: 1152
Study 19847131 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy combined with an intensive rehabilitation program
Number of subjects: 21
Study 19847131 — intervention group
Group type: COMPARATOR
Intervention: Intensive rehabilitation program
Number of subjects: 21
Study 19847131 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 21
Study 18229570 — intervention group
Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 58
Study 18229570 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Anxiety Inventory (BAI)
Number of subjects: 58
Study 18229570 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, 2nd edition (BDI)
Number of subjects: 58
Study 18229570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 58
Study 18229570 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 58
Study 15499762 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0
Study 15499762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11905959 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (600 mg alpha‐tocopherol, 1000 mg ascorbic acid, 32 mg beta‐carotene)
Number of subjects: 13
Study 11905959 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 13
Study 9337497 — intervention group
Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 98
Study 9337497 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention (RP)
Number of subjects: 98
Study 7944656 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant total parenteral nutrition
Number of subjects: 0
Study 7944656 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant total parenteral nutrition (Control)
Number of subjects: 0
Study 2904825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10‐20 mg)
Number of subjects: 14
Study 2904825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50‐100 mg)
Number of subjects: 14
Study 29164399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high molecular weight hyaluronic acid (UHMW-HA, Fermathron S)
Number of subjects: 54
Study 29164399 — intervention group
Group type: COMPARATOR
Intervention: Medium molecular weight hyaluronan (MMW-HA, Hyalubrix 60)
Number of subjects: 54
Study 29164399 — intervention group
Group type: COMPARATOR
Intervention: MMW-HA (subgroup analysis)
Number of subjects: 54
Study 27575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention
Number of subjects: 178
Study 27575791 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face delivered intervention
Number of subjects: 178
Study 27575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapeutic alliance
Number of subjects: 178
Study 27575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 178
Study 27575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment retention
Number of subjects: 178
Study 24692284 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 301
Study 24692284 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 301
Study 22687601 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus lapatinib
Number of subjects: 579
Study 22687601 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 579
Study 20727091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of specific training
Number of subjects: 51
Study 18272892 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons
Number of subjects: 154
Study 18272892 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel in contrast medium
Number of subjects: 154
Study 18272892 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated balloons without paclitaxel)
Number of subjects: 154
Study 16379563 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax fiber supplement (15 g/day)
Number of subjects: 26
Study 16379563 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplement (10.4 g/day)
Number of subjects: 26
Study 16379563 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax bread
Number of subjects: 26
Study 16379563 — intervention group
Group type: COMPARATOR
Intervention: Control white bread
Number of subjects: 26
Study 12784171 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise to determine maximal aerobic velocity (MAV)
Number of subjects: 30
Study 12784171 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load exercise at 90% MAV
Number of subjects: 30
Study 12784171 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load exercise at 100% MAV
Number of subjects: 30
Study 12784171 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest perceived exertion ratings
Number of subjects: 30
Study 12784171 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR) values
Number of subjects: 30
Study 10561205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with tamoxifen
Number of subjects: 2016
Study 10561205 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without tamoxifen
Number of subjects: 2016
Study 10561205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without tamoxifen
Number of subjects: 2016
Study 8736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1301365 — intervention group
Group type: EXPERIMENTAL
Intervention: Head reorientation 2 seconds after cessation of head rotation
Number of subjects: 10
Study 1301365 — intervention group
Group type: COMPARATOR
Intervention: Postrotatory nystagmus (PRN)
Number of subjects: 10
Study 3889258 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally)
Number of subjects: 17
Study 3889258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31022110 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 12278
Study 30372830 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (50 mg/kg infused intravenously within 15 min)
Number of subjects: 60
Study 30372830 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same volume as MgSO4)
Number of subjects: 60
Study 25128211 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led intervention
Number of subjects: 641
Study 25128211 — intervention group
Group type: EXPERIMENTAL
Intervention: RHS-led intervention
Number of subjects: 641
Study 25128211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening score improvement by 3 levels (irrespective of group allocation)
Number of subjects: 641
Study 22336878 — intervention group
Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine (30 μg dose)
Number of subjects: 0
Study 22336878 — intervention group
Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine (1 mg dose)
Number of subjects: 0
Study 22336878 — intervention group
Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine
Number of subjects: 0
Study 19703327 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (220 mg/d)
Number of subjects: 119
Study 19703327 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg each/d)
Number of subjects: 119
Study 19703327 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 119
Study 17589194 — intervention group
Group type: EXPERIMENTAL
Intervention: MDOT
Number of subjects: 87
Study 17589194 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 87
Study 15760635 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 7
Study 15760635 — intervention group
Group type: COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS) over the left motor cortex (MC)
Number of subjects: 7
Study 12377399 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (0.66 mg/kg, maximum dose of 500 mg)
Number of subjects: 13
Study 12377399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12377399 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia group (baseline results from 17 drug-treated patients)
Number of subjects: 13
Study 10463785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (1 ml 30% glucose) prior to skin puncture
Number of subjects: 120
Study 10463785 — intervention group
Group type: COMPARATOR
Intervention: Heel stick without oral glucose
Number of subjects: 120
Study 10463785 — intervention group
Group type: COMPARATOR
Intervention: Venepuncture without oral glucose
Number of subjects: 120
Study 8157401 — intervention group
Group type: EXPERIMENTAL
Intervention: Softened fabrics (washed with liquid fabric softener)
Number of subjects: 24
Study 8157401 — intervention group
Group type: COMPARATOR
Intervention: Unsoftened fabrics (washed with granular detergent)
Number of subjects: 24
Study 2688080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam suppositories (20 mg once daily)
Number of subjects: 48
Study 2688080 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam suppositories (20 mg once daily)
Number of subjects: 48
Study 31926605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (0.25 mg/3 h)
Number of subjects: 33